Quarterly report · Q2
9273.TEDINET S100SVUE
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.4bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.2bn | 2022-07-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.1bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.2bn | 2022-07-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2022-07-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥1.4bn | 2022-07-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥29.6bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥27.6bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.7bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥7.5bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥22.0bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.9bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥19.6bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.0bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.4bn | at 2022-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥518m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥644m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥304m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥120m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥639m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥812m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥600m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥39.46 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.34 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.83 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.19 | 2022-07-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.9 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 74.2% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.8% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥38m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥7.9bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥7.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.0bn |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥12.3bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥11.4bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | ¥2.4bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-12-31 | −¥925m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-12-31 | −¥925m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-12-31 | ¥22m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥8.1bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥7.2bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥925m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥4.0bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥761m |
| —segment total | revenue | 2022-07-01 → 2022-12-31 | ¥12.1bn |
| —segment total | revenue external | 2022-07-01 → 2022-12-31 | ¥11.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥925m |
| —segment total | segment profit | 2022-07-01 → 2022-12-31 | ¥2.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 493
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes paid ope cf | Prior1YTDDuration | -795361000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -795596000 | JPY |
| Income taxes refund ope cf | Prior1YTDDuration | － | JPY |
| Income taxes refund ope cf | CurrentYTDDuration | 91733000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 518384000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 1540318000 | JPY |
| Purchase of noncurrent assets inv cf | Prior1YTDDuration | -104085000 | JPY |
| Purchase of noncurrent assets inv cf | CurrentYTDDuration | -628193000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -85011000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -91012000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 72011000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 78011000 | JPY |
| Other net inv cf | Prior1YTDDuration | -2698000 | JPY |
| Other net inv cf | CurrentYTDDuration | -3125000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -119784000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -644320000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -150952000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -150952000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -436130000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -475266000 | JPY |
| Other net fin cf | Prior1YTDDuration | -12971000 | JPY |
| Other net fin cf | CurrentYTDDuration | -12890000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -600053000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -639109000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 416000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -609000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -201037000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 256279000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 8421859000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 10035504000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 8220822000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 10291783000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 109356000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 110507000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 284014000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 280566000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 10163000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 12928000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 25205000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 26472000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 6216000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 6514000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 7172413000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 3994560000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 11166974000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 11166974000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 924850000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 924850000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |